Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TLR4 single nucleotide polymorphisms may play an important protective role in the development of hepatocellular carcinoma.
|
21559380 |
2011 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TLR4 was overexpressed in HCC cell lines and in human HCC tissues, where it correlated with Ki-67 expression.
|
23828139 |
2013 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TLR4-mediated BCL6 upregulation was crucial for PD-1(hi) B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation.
|
26928313 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
TLR4 on macrophages contributes to the development of steatohepatitis-related HCC in mice.
|
27022031 |
2016 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TLR4 is an innate immunity receptor which plays a pathogenic role during chronic inflammation and can induce HCC in human.
|
28472619 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Toll-like receptor 4 (TLR4) appears to play an important role in the development and progression of hepatocellular carcinoma (HCC), but it is unclear whether single-nucleotide polymorphisms (SNPs) in the TLR4 gene influence HCC.
|
28945461 |
2017 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, high expression of TLR4 in HCC tissues was strongly associated with both early recurrence and poor survivals in patients.
|
25511737 |
2015 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Baishouwu Extract Suppresses the Development of Hepatocellular Carcinoma via TLR4/MyD88/NF-κB Pathway.
|
31068809 |
2019 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Both down-regulation of miR-122 and up-regulation of TLR4 were found to be correlated with low overall survival rate of HCC patients.
|
31477445 |
2020 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the expression of TLR4 was detected in the peripheral blood mononucleated cell of hepatocellular carcinoma (HCC) patients, suggesting that mRNA and protein levels of TLR4 might be associated with SNP rs1057317.
|
25179842 |
2014 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
|
22516259 |
2012 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Haplotypes CAGT of TLR4 and ATAC of TLR2 showed significant association with CH and HCC groups in comparison to other groups.
|
31615295 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
HBsAg/β2GPI activates the NF‑κB pathway via the TLR4/MyD88/IκBα axis in hepatocellular carcinoma.
|
29916535 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of TLR4 on M2-polarized macrophages in hepatocellular carcinoma (HCC) are unknown.
|
29338742 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human hepatocellular carcinoma cells (HepG2 and HuH7) were incubated in media including 2% bovine serum albumin and 250 to 1000 μM palmitate for 24 h. Signaling mediated by TLR4 was blocked by a TLR4 decoy peptide or small interfering RNA knockdown of TLR4.
|
23465595 |
2013 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry confirmed increased expression of TLR2 and TLR4 in hepatitis and cirrhosis and maintained expression in hepatocarcinoma.
|
22330637 |
2012 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, TLR4 is functionally expressed in HCC cells and promotes HCC cell proliferation, which can be regulated by miR-146a.
|
31612014 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our analysis disclosed the immune subversion was the major signature of HCC associated closely with JUN, VEGFA, TNFSF10, and TLR4, which could be novel noninvasive biomarkers in peripheral blood and targets for early diagnosis and therapy of HCC.
|
31531018 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the current results suggested that the TLR4/MyD88 signaling pathway is involved in HCC cell proliferation and metastasis via regulation of the IL-23/IL-17A axis; thus, the TLR4/IL-23/IL-17A pathway may represent a novel therapeutic target in HCC.
|
29928340 |
2018 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In multivariate logistic regression analysis, Milan criteria, microvascular invasion and donor TLR4 rs1927914 genotype were confirmed to be independent risk factors for HCC recurrence.
|
29221801 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Involvement of TLR4/ CXCL9/ PREX-2 pathway in the development of hepatocellular carcinoma (HCC) and the promising role of early administration of lactobacillus plantarum in Wistar rats.
|
31582017 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Modulation of the gut-liver axis and the LPS-Tlr4 response by RIPC, gut sterilization, and Tlr4 antagonism represents a potential therapeutic target to prevent I/R lesions, and to alleviate HCC recurrence after liver transplantation and resection.
|
29331341 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stimulation of Toll-like receptor 4 (TLR4) by bacterial lipopolysaccharide (LPS) initiates inflammation and promotes development of hepatocellular carcinoma and other liver diseases.
|
29085012 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that the activated TLR4/NANOG oncogenic pathway is linked to suppression of cytostatic TGF-β signaling and could potentially serve as a therapeutic target for HCV-related HCC.
|
23921128 |
2013 |
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TLR4 rs2148356 T allele is associated with a reduced risk of HCC and could slow down its clinical progression in HCV-induced chronic liver disease.
|
22286521 |
2012 |